Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242

Lysosome-targeting chimaeras for degradation of extracellular proteins

Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923

Synthetic Multivalent Ligands as Probes of Signal Transduction

Kiessling, L. L., Gestwicki, J. E., & Strong, L. E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502794 · Cited by 864

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852

PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830

Application of PROTACs in target identification and validation

Liu, Y., Liang, J. Y., Zhu, R., Yang, Y., Wang, Y., Wei, W., Li, H., & Chen, L. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0010 · Cited by 21

Ternary Complex‐Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo‐PROTACs

Diehl, C. J., Salerno, A., & Ciulli, A. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202319456 · Cited by 18

Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo

Luo, T., Zheng, Q., Shao, L., Ma, T., Mao, L., & Wang, M. (2022) · Angewandte Chemie · doi:10.1002/ange.202206277 · Cited by 18

Kinetic Modeling of PROTAC‐Induced Protein Degradation

Zhao, H., & Narjes, F. (2023) · ChemMedChem · doi:10.1002/cmdc.202300530 · Cited by 18

Transcriptome-Wide, Unbiased Profiling of Ribonuclease Targeting Chimeras

Tong, Y., Su, X., Rouse, W. B., Childs‐Disney, J. L., Taghavi, A., Zanon, P. R. A., Kovachka, S., Wang, T., Moss, W. N., & Disney, M. D. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04717 · Cited by 20

Cellular parameters shaping pathways of targeted protein degradation

Cardno, A., Kennedy, B., & Lindon, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08104-w · Cited by 22

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17

Programming conformational cooperativity to regulate allosteric protein-oligonucleotide signal transduction

Liang, Y., Qie, Y., Yang, J., Wu, R., Cui, S., Zhao, Y., Anderson, G. J., Nie, G., Li, S., & Zhang, C. (2023) · Nature Communications · doi:10.1038/s41467-023-40589-z · Cited by 17

A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function

Xu, Y., Fu, D., Yuan, Y., Peng, Y., Dong, J., Du, F., Huang, X., Li, G., Chen, X., Wang, Q., et al. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101064 · Cited by 17

Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2

Hoffman, M., Krum, D., & Wittrup, K. D. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107616 · Cited by 16

A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines

Huang, L., Sun, X., Zuo, Q., Song, T., Liu, N., Liu, Z., & Xue, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101523 · Cited by 16

Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines

Yan, Z., Lyu, X., Lin, D., Wu, G., Gong, Y., Ren, X., Xiao, J., Lou, J., Huang, H., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115381 · Cited by 14

Quantitative Measurement of Rate of Targeted Protein Degradation

Lynch, T. L., Marin, V. L., McClure, R. A., Phipps, C. J., Ronau, J. A., Rouhimoghadam, M., Adams, A. M., Kandi, S., Wolke, M. L., Shergalis, A. G., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00262 · Cited by 16

Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer

Shi, Y., Shen, Q., Long, R., Mao, Y., Tong, S., Yang, Y., Gao, J., Zhou, H., Chen, Y., & Zhou, B. N. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01192 · Cited by 14

Discovery of PRMT3 Degrader for the Treatment of Acute Leukemia

Zou, W., Li, M., Wan, S., Ma, J., Lian, L., Luo, G., Zhou, Y., Li, J. X., & Zhou, B. N. (2024) · Advanced Science · doi:10.1002/advs.202405963 · Cited by 14

Conquering PROTAC molecular design and drugability

Bhole, R. P., Labhade, S., & Gurav, S. S. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2481021 · Cited by 14

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology

Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 14

Membrane‐Bounded Intracellular E3 Ubiquitin Ligase‐Targeting Chimeras (MembTACs) for Targeted Membrane Protein Degradation

Mo, M., Wang, F., Zhang, H., Zhang, Y., Yang, C. J., Shang, J., & Zhu, Z. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202501857 · Cited by 13

Programmable PROTAC delivery for precise and spatiotemporal protein degradation

Sheng, J., Ma, T., Wu, Y., & Wang, M. (2026) · Chemical Communications · doi:10.1039/d5cc05651a · Cited by 13

Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy

Zhang, N., Hou, D., Hu, X., Liang, J., Wang, M., Song, Z., Li, Y., Wang, Z., An, H., Xu, W., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202308049 · Cited by 14

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors

Dai, M., Sridhar, R., Li, R., Tan, R., Yan, K., Fan, G., & Liu, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221095950 · Cited by 14

Recent Advances in PROTAC Technology Toward New Therapeutic Modalities

Yokoo, H., Naganuma, M., Oba, M., & Demizu, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200828 · Cited by 14

Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing

Altinbay, M., Wang, J., Chen, J., Schäfer, D., Sprang, M., Blagojevic, B., Wölfl, S., Andrade-Navarro, M. A., Đikić, I., Knapp, S., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae798 · Cited by 14

PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows

Haid, R. T. U., & Reichel, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104311 · Cited by 17

N-Acetylenethio phthalimides: Sequential linkage for compositional click reaction

Gao, W., Feng, K., Tian, J., Zhang, J., Chang, H., & Jiang, X. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.010 · Cited by 12

Recent advances and strategies in BET bromodomain inhibition for drug discovery

Zhang, P.-F., Li, Y.-S., Wang, C., Gao, Y., Liu, J., Zhang, H.-E., Shi, L., & Sun, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118230 · Cited by 12

High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders

Peng, X., Li, Y., Qu, J., Jiang, L., Wu, K., Liu, D., Chen, Y., Peng, J., Guo, Y., & Cao, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116405 · Cited by 11

Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs

Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13

A comprehensive primer and review of PROTACs and their In Silico design

Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 14

Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research

Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025) · Small Methods · doi:10.1002/smtd.202500402 · Cited by 13

Bifunctional robots inducing targeted protein degradation

Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11

Controllable multivalent LYTACs enhance targeted protein degradation

Lv, Y., Li, Y., Fu, Q., & Shi, P. (2024) · Chemical Communications · doi:10.1039/d4cc04842c · Cited by 12

Opportunities in proximity modulation: Bridging academia and industry

Đikić, I., Mayor‐Ruiz, C., Winter, G. E., Koch, K., Ciulli, A., & Thomä, N. H. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.018 · Cited by 10

The 17 th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders

Ciulli, A., O’Connor, S., Chung, C., Hartung, I. V., Testa, A., Daniels, D. L., & Heitman, L. H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300464 · Cited by 9

PROTACs targeting epigenetic proteins

Zhang, C., He, Y., Sun, X., Wei, W., Liu, Y., & Rao, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0039 · Cited by 13

Proteolysis-Targeting Chimera Molecules Targeting SHP2

Yu, D., Zheng, M., Liu, Y., Chen, L., & Li, H. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0324 · Cited by 9

Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains

Huang, C., Harris, C. L., Siddiqui, G., & Jörg, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00726 · Cited by 8

Bacterial enzymes: powerful tools for protein labeling, cell signaling, and therapeutic discovery

Liu, L., Gray, J. L., Tate, E. W., & Yang, A. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.05.004 · Cited by 8

Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy

De, S., Sahu, R., Palei, S., & Nanda, L. N. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117875 · Cited by 9

Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK Degradation

Wu, M., Mao, X., Wu, Y., Wang, W.-T., Jin, Y., Yu, H., Hu, L., Shen, Z., Shen, L., Zeng, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02972 · Cited by 9

COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies

Reboud‐Ravaux, M., & Amri, C. E. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.892057 · Cited by 8

The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events

Hollingsworth, S. A., Johnson, S. A., Khakbaz, P., Meng, Y., Mouchlis, V. D., Pierce, O., Prytkova, V. D., Vik, E. S., Weiss, D. R., & Shanmugasundaram, V. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03104-z · Cited by 11

New Frontiers in the Discovery and Development of PROTACs

Barghout, S. H. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220412132759 · Cited by 8

PROTAC Degraders

Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 8

Atomic-Resolution Prediction of Degrader-mediated Ternary Complex Structures by Combining Molecular Simulations with Hydrogen Deuterium Exchange

Dixon, T., MacPherson, D., Mostofian, B., Dauzhenka, T., Lotz, S., McGee, D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2021) · doi:10.1101/2021.09.26.461830 · Cited by 7

Use of Aldehyde–Alkyne–Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers

McGown, A., Vetma, V., Crépin, D., Lin, Y., Adcock, C., Craigon, C., Nafie, J., von Emloh, D., Sutton, L., Bailey, K., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00531 · Cited by 8

Chemically synthesized phosphorylated ubiquitin unlocks parkin for activation-controlled PROTAC platforms

Chen, F., Zhan, Q., Qu, Q., Cui, S., Weng, Y., Pan, M., Zheng, Q., Hu, H., & Yu, Y. (2025) · Science China Chemistry · doi:10.1007/s11426-025-2762-0 · Cited by 7

A Multi-Split-and-Mix Platform for a Variety of Targeted Protein Degradation

Wang, Y., Luo, Q., Xing, Y., Wang, R. Y., Yang, F., Cao, W., Li, Z., & Yin, F. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00444 · Cited by 7

Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs

Zhang, S.-H., Zeng, N., Xu, J., Liu, C., Xu, M., Sun, J., An, Y., Zhong, X., Miao, L.-T., Wang, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117584 · Cited by 9

DUB be good to me

Liu, X., & Ciulli, A. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00978-9 · Cited by 7

Major Advances in Emerging Degrader Technologies

Luo, H., Wu, L., He, Y., Qin, C., & Tang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.921958 · Cited by 7

Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies

Wu, Y., Zhang, J., Zhu, X., & Zhang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215808 · Cited by 8

Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders

Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6

Linkerology in PROTACs: learnings for proximity-inducing therapeutics

Prieto‐Díaz, R., Urbina, A., Rodriguez-Rios, M., & Ciulli, A. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.07.004 · Cited by 7

Chemical immunology: Recent advances in tool development and applications

Shi, Y., Bashian, E. E., Hou, Y., & Wu, P. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.006 · Cited by 6

Protocol for the comprehensive biochemical and cellular profiling of small-molecule degraders using CoraFluor TR-FRET technology

Payne, N. C., Ichikawa, S., Woo, C. M., & Mazitschek, R. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103129 · Cited by 7

Selectivity Profiling of Bromodomain PROTACs Using Chemical Inducers of Proximity DNA-Encoded Library Screening

Chow, Y. T., Tong, B., Tan, Z. Y., Tutter, A. V., Nan, Z., Horton, P. A., Romanowski, M. J., Zécri, F. J., Schreiber, S. L., & Liu, S. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00413 · Cited by 5

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68913-3 · Cited by 7

Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation

Zhang, N., Liang, J.-X., Hu, B.-N., Wang, Y., An, H., & Wang, H. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115861 · Cited by 5

Modular Assembly of Heterotrifunctional Molecules Enabled by Iodosulfonylation of Allenes and Subsequent Amination

Lin, X., Peng, C., Liu, S., Xiang, J., Lin, B., Zhan, Q., Cao, P., & Cao, T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02114 · Cited by 5

Utilizing Alkyne‐Nitrone Cycloaddition for the Convenient Multi‐Component Assembly of Protein Degraders and Biological Probes

Lin, S., Wang, C., Chen, A., & Wang, T. A. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202403184 · Cited by 5

HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase

Sarnow, A., Nassar, H., Alfayomy, A. M., Robaa, D., & Sippl, W. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110570 · Cited by 4

Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis

Wang, Y., Zheng, J., Long, Y., Wu, W., & Zhu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115989 · Cited by 5

Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?

Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5

CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity

Wang, K., Diaz, S., Li, L., Lohman, J. R., & Liu, X. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01167-5 · Cited by 5

Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy

Zhang, X., Song, Z., Zhang, X., Zou, J., Yu, G., Chen, X. S., & Wang, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202507702 · Cited by 5

PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery

Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4

A Tandem-Affinity Purification Method for Identification of Primary Intracellular Drug-Binding Proteins

Islam, S., Gour, J., Beer, T., Tang, H., Cassel, J. A., Salvino, J. M., & Busino, L. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00570 · Cited by 5

Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs

Cao, Y., Harris, A. L., & Ciulli, A. (2025) · Nature Protocols · doi:10.1038/s41596-025-01283-0 · Cited by 6

Computational Modeling of PROTAC Ternary Complexes and Linker Design

Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch5 · Cited by 4

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Baker, A., Ho, A. P. T., Itzhaki, L. S., & Fruk, L. (2025) · Angewandte Chemie · doi:10.1002/ange.202503958 · Cited by 3

Targeted protein degradation of HSP90 and associated proteins for cancer therapy via PROTACs and beyond

Kumar, G., Tyagi, G., & Monga, V. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00369e · Cited by 3

Modular Assembled Targeting Chimera Enables Multimodal Targeted Protein Degradation

Zhu, W., Zhang, W., Wang, Y., Chen, J., Xu, F., & Pang, J. (2025) · JACS Au · doi:10.1021/jacsau.5c01131 · Cited by 3

Diversified design strategies for small-molecule PROTACs: How do we select?

Chen, Q., & Liang, J.-H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118593 · Cited by 3

Insulin‐like Growth Factor 2‐Tagged Aptamer Chimeras (ITACs) Modular Assembly for Targeted and Efficient Degradation of Two Membrane Proteins

Tian, Y., Miao, Y., Guo, P., Wang, J., & Han, D. (2023) · Angewandte Chemie · doi:10.1002/ange.202316089 · Cited by 3

Advancing PROTAC Characterization: Structural Insights through Adducts and Multimodal Tandem-MS Strategies

Rahman, M. K., Marzullo, B. P., Holman, S. W., Barrow, M. P., Ray, A. D., & O’Connor, P. B. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00342 · Cited by 4

Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases

Ji, Y., Chen, W., & Wang, X. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002036 · Cited by 3

Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives

Yan, X. Y., Kang, Y. Y., Zhang, Z. Y., Huang, P. C., Yang, C., & Naranmandura, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443577 · Cited by 3

Facile Synthesis of Homodimeric Protein Ligands

Gui, W., & Kodadek, T. J. (2023) · ChemBioChem · doi:10.1002/cbic.202300392 · Cited by 3

Target Protein Localisation and Its Impact on PROTAC-Mediated DegradationPreprint

Simpson, L. M., Glennie, L., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4006704 · Cited by 3

Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint

Ghosal, S., Robertus, C. M., Wang, J., Chan, H. W., Alamgir, A., Almonte, J., & Alabi, C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.17.584721 · Cited by 5

N-Degron PROTACs as a Potential Therapeutic Approach for Chronic Myeloid Leukemia

Hohman, G., & Eldeeb, M. A. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206367166241230111659 · Cited by 2

Unraveling the secrets of novel PROTACs to improve degradation efficacy

Huang, J., Yang, X., Huang, Q., Gao, Y., Bandaranayake, P. C. G., Kandegama, W. M. W. W., Ashby, C. R., Dong, Y., Wang, Z., & Hao, G. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11273-9 · Cited by 3

The past, present, and future of ALK-targeted drug discovery

Qu, H., Zhang, J., Zhao, X., Ge, X., Duan, L., & Yuan, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118053 · Cited by 2

Chromatin Regulatory Targets for Anticancer Therapeutics

Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Yang, J., Zhang, Y., Zhang, M., Xing, D., & Wang, C. (2025) · Materials Today Advances · doi:10.1016/j.mtadv.2025.100644 · Cited by 4

Chemistry-Driven Integrated Innovation: Unleashing the Potential of PROTAC Technology

Xu, H., Tang, K., Song, Y., Menéndez‐Arias, L., & Zhan, P. (2025) · Pharmaceutical Fronts · doi:10.1055/a-2731-6203 · Cited by 2

Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs

Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4

Dual / bifunctional targeting of bromodomain and extra-terminal (BET) proteins: Expanding the paradigm of epigenetic drug discovery

Jiang, F., Li, H., Sun, Q., Huang, J., Chen, X., Liang, Q., Luo, X., Zhang, W., He, D., & Shen, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118524 · Cited by 3

Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies

Zhang, Y., Lu, D., Zhang, L., Shao, Y., Yan, Z., & Liu, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117716 · Cited by 2

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia

Wei, Q., Zhang, J., Chen, J., Cai, X., 周金培, Wang, B., Zhang, H., & Cao, P. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118667 · Cited by 2

Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets

Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3

Histone modifications across cancers: mechanisms, therapy and clinical translation

Lu, P., Chan, Y.-T., Kwok, C.-F., Li, Q., Jiang, Z., Xu, L., Feng, Z., Yuan, H., Zou, J., Xun, Y., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02707-5 · Cited by 3

Emerging pharmacology of targeted protein degraders

Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2

Ternary Complex‐Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo‐PROTACs

Diehl, C. J., Salerno, A., & Ciulli, A. (2024) · Angewandte Chemie · doi:10.1002/ange.202319456 · Cited by 1

Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70427 · Cited by 2

Indirect ubiquitination independent of endogenous ubiquitination machinery for targeted protein degradation

Furuhata, T., Yoshida, K., 凌嘉, 藤., Miyamoto, J., Moriyama, C., Masuda-Ozawa, T., Tsuchiya, H., Saeki, Y., & Okamoto, A. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01895-x · Cited by 1

PROTAC-based protein degradation: a window of opportunity for melanoma therapy

Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1

Unnatural amino acid-based miniPROTACs enable efficient oncoprotein degradation

Zhang, J., Chen, X., Chen, C., Li, F., Liao, K., Song, X., Zeng, Y., Wang, J., Su, M.-Y., Tan, C. S. H., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.022 · Cited by 1

Research progress and future perspectives in proteolysis-targeting chimeras

Wu, N., Xu, Z., Dai, S., & Wang, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815569 · Cited by 1

Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint

Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695.v1 · Cited by 3

Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation

Wurz, R. P., Rui, H., Dellamaggiore, K., Ghimire-Rijal, S., Choi, K., Smither, K., Amegadzie, A. K., Chen, N., Li, X., Banerjee, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39904-5 · Cited by 175

Targeted Protein Degradation with Small Molecules: How PROTACs Work

Ciulli, A. (2019) · Molecules Medicinal Chemistry Symposium (MMCS) · doi:10.3390/proceedings2019022115 · Cited by 1

Techniques for Accelerating the Understanding of PROTAC-Based Ternary Complex

Ullah, I., Gao, J., & Yuan, Y. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_840

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera

Bond, A. G., Ordoño, M. M. I., Bisbach, C. M., Craigon, C., Makukhin, N., Caine, E. A., Nagala, M., Urh, M., Winter, G. E., Riching, K. M., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11556 · Cited by 40